Evaluation of [18F]CP18 as a Substrate-Based Apoptosis Imaging Agent for the Assessment of Early Treatment Response in Oncology

[1]  P. Vermeulen,et al.  Early Prediction of Tumor Response to Treatment: Preclinical Validation of 99mTc-Duramycin , 2016, The Journal of Nuclear Medicine.

[2]  J. Miller,et al.  Imaging Caspase-3 Activation as a Marker of Apoptosis-Targeted Treatment Response in Cancer , 2015, Molecular Imaging and Biology.

[3]  B. Gray,et al.  Characterization of [99mTc]Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor Apoptosis , 2015, Molecular Imaging and Biology.

[4]  B. Tamarappoo,et al.  Noninvasive Molecular Imaging of Apoptosis in a Mouse Model of Anthracycline-Induced Cardiotoxicity , 2015, Circulation. Cardiovascular imaging.

[5]  S. Dedeurwaerdere,et al.  In vivo evaluation of (18)F-labeled TCO for pre-targeted PET imaging in the brain. , 2014, Nuclear medicine and biology.

[6]  C. Sirtori,et al.  Magnetic Resonance Imaging Visualization of Vulnerable Atherosclerotic Plaques at the Brachiocephalic Artery of Apolipoprotein E Knockout Mice by the Blood-Pool Contrast Agent B22956/1 , 2014, Molecular imaging.

[7]  Nizar M. Mhaidat,et al.  5-Fluorouracil-induced apoptosis in colorectal cancer cells is caspase-9-dependent and mediated by activation of protein kinase C-δ , 2014, Oncology letters.

[8]  E. Aboagye,et al.  Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by 18F-ICMT-11-Positron Emission Tomography , 2014, PloS one.

[9]  M. Washington,et al.  A Peptide-Based Positron Emission Tomography Probe for In Vivo Detection of Caspase Activity in Apoptotic Cells , 2014, Clinical Cancer Research.

[10]  Mohan Doss,et al.  Biodistribution and Radiation Dosimetry of 18F-CP-18, a Potential Apoptosis Imaging Agent, as Determined from PET/CT Scans in Healthy Volunteers , 2013, The Journal of Nuclear Medicine.

[11]  J. Gubbins,et al.  Temporal and Spatial Evolution of Therapy-Induced Tumor Apoptosis Detected by Caspase-3–Selective Molecular Imaging , 2013, Clinical Cancer Research.

[12]  H. Kolb,et al.  In Vitro and In Vivo Evaluation of the Caspase-3 Substrate-Based Radiotracer [18F]-CP18 for PET Imaging of Apoptosis in Tumors , 2013, Molecular Imaging and Biology.

[13]  H. Kolb,et al.  Evaluation of [18F]-CP18 as a PET Imaging Tracer for Apoptosis , 2013, Molecular Imaging and Biology.

[14]  Zhixin Li,et al.  A single-step kit formulation for the (99m)Tc-labeling of HYNIC-Duramycin. , 2012, Nuclear medicine and biology.

[15]  C. Reutelingsperger,et al.  Single-Photon Emission Computed Tomographic Imaging of the Early Time Course of Therapy-Induced Cell Death Using Technetium 99m Tricarbonyl His-Annexin A5 in a Colorectal Cancer Xenograft Model , 2012, Molecular imaging.

[16]  Manuel T. Silva.  Secondary necrosis: The natural outcome of the complete apoptotic program , 2010, FEBS letters.

[17]  J. Philippé,et al.  In vitro and in vivo evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells. , 2010, Nuclear medicine and biology.

[18]  E. Aboagye,et al.  Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide , 2009, Proceedings of the National Academy of Sciences.

[19]  F. Blankenberg,et al.  Monitoring of treatment-induced apoptosis in oncology with PET and SPECT. , 2008, Current pharmaceutical design.

[20]  S. Elmore.  Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[21]  N. Lameire.  THE KIDNEY IN ONCOLOGY , 2007, Acta clinica Belgica.

[22]  Dmitri V. Krysko,et al.  Clearance of apoptotic and necrotic cells and its immunological consequences , 2006, Apoptosis.

[23]  J. Verweij,et al.  Renal toxicities of chemotherapy. , 2006, Seminars in Oncology.

[24]  Howard L McLeod,et al.  Therapeutic Synergy Between Irinotecan and 5-Fluorouracil against Human Tumor Xenografts , 2004, Clinical Cancer Research.

[25]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[26]  L. Montanaro,et al.  Evaluation of Thymidylate Synthase Protein Expression by Western Blotting and Immunohistochemistry on Human Colon Carcinoma Xenografts in Nude Mice , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[27]  P. Thimister,et al.  Visualization of cell death in vivo with the annexin A5 imaging protocol. , 2002, Journal of immunological methods.

[28]  M. Rothenberg.  Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond. , 2001, The oncologist.

[29]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[30]  H E Rockette,et al.  The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Stroobants,et al.  Continuous Flushing of the Bladder in Rodents Reduces Artifacts and Improves Quantification in Molecular Imaging. , 2014, Molecular imaging.